Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.

[1]  A. Favero,et al.  Prevention of cisplatin-induced emesis , 1992, The Lancet.

[2]  J. Hainsworth,et al.  A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Amadori,et al.  Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Tonato,et al.  Methodology of antiemetic trials: a review. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. Lazarus,et al.  Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. , 1990, Journal of the National Cancer Institute.

[6]  L. Cubeddu,et al.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. , 1990, The New England journal of medicine.

[7]  J. Droz,et al.  Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. , 1990, The New England journal of medicine.

[8]  F. di Costanzo,et al.  Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Groshen,et al.  Antiemetic control and prevention of side effects of anti‐cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double‐blind, randomized trial , 1987, Cancer.

[10]  R. Gralla,et al.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. , 1981, The New England journal of medicine.

[11]  T. Robak.  [Clinical pharmacology of ondansetron]. , 1993, Acta haematologica Polonica.

[12]  M. Tonato,et al.  Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. , 1991, European journal of cancer.

[13]  M. Soukop.  A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. , 1990, European journal of cancer.

[14]  E. Díaz-Rubio,et al.  Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis. , 1990, Annals of Oncology.

[15]  R. D. Myers,et al.  Do humoral factors mediate cancer chemotherapy-induced emesis? , 1989, Drug metabolism reviews.

[16]  P. Colthup,et al.  The determination in plasma and pharmacokinetics of ondansetron. , 1989, European journal of cancer & clinical oncology.

[17]  P. Dobkin,et al.  Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions☆ , 1988 .

[18]  F. Artigas,et al.  Serotonergic status in human blood. , 1988, Life sciences.

[19]  P. Elteren.  On the combination of independent two-sample tests of wilcoxon : Corrected version , 1959 .